Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 252

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

Open access
Burger, Matthew T., Pecchi, Sabina, Wagman, Allan, Ni, Zhi-Jie, Knapp, Mark, Hendrickson, Thomas, Atallah, Gordana, Pfister, Keith, Zhang, Yanchen, Bartulis, Sarah, Frazier, Kelly, Ng, Simon, Smith, Aaron, Verhagen, Joelle, Haznedar, Joshua, Huh, Kay, Iwanowicz, Ed, Xin, Xiaohua, Menezes, Daniel, Merritt, Hanne, Lee, Isabelle, Wiesmann, Marion, Kaufman, Susan, Crawford, Kenneth, Chin, Michael, Bussiere, Dirksen, Shoemaker, Kevin, Zaror, Isabel, Maira, Sauveur-Michel, Voliva, Charles F. · 2011 · ACS Medicinal Chemistry Letters

Abstract

Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent. The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma). These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clinical trials for the treatment of cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/ml200156t

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 252

Metadata

Authors
Burger, M. T., Pecchi, S., Wagman, A., Ni, Z.-J., Knapp, M., Hendrickson, T., Atallah, G., Pfister, K., Zhang, Y., Bartulis, S., Frazier, K., Ng, S., Smith, A., Verhagen, J., Haznedar, J., Huh, K., Iwanowicz, E., Xin, X., Menezes, D., Merritt, H., Lee, I., Wiesmann, M., Kaufman, S., Crawford, K., Chin, M., Bussiere, D., Shoemaker, K., Zaror, I., Maira, S.-M., & Voliva, C. F.
Venue
ACS Medicinal Chemistry Letters
Published
2011-08-26
Volume
2
Issue
10
Pages
774-779
ISSN
1948-5875 (ISSN-L)
OpenAlex
W2018872626
Cited by
252
References
13
FWCI
2.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. https://app.cochat.ai/papers/10.1021/ml200156t
The paper
Burger, M. T., Pecchi, S., Wagman, A., Ni, Z.-J., Knapp, M., Hendrickson, T., Atallah, G., Pfister, K., Zhang, Y., Bartulis, S., Frazier, K., Ng, S., Smith, A., Verhagen, J., Haznedar, J., Huh, K., Iwanowicz, E., Xin, X., Menezes, D., . . . Voliva, C. F. (2011). Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/ml200156t

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.